Intranasal administration of olanzapine has beneficial outcome in a rat activity-based anorexia model

Kooij, K.; Luijendijk, Mieneke C. M.; Drost, Lisa; Platenburg, Gerard; Elburg, Annemarie van; Adan, Roger A.H.

doi:10.1016/j.euroneuro.2023.03.008

Cited by 2 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another advantage of the ABA model is its usefulness to test drugs such as olanzapine, ketamine, dronabinol, psilocybin, or leptin, which are considered promising candidates for medical interventions in AN, despite not being fully approved for such use [ 32 ]. Treating ABA mice with the atypical antipsychotic olanzapine [ 33 , 34 , 35 ] or ketamine [ 36 ] enhanced the survival of ABA animals. Treatment with dronabinol, Δ 9 -tetrahydrocannabinol (THC), reduced survival of these animals; however, food intake was higher in survivors [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Establishment of a Murine Chronic Anorexia Nervosa Model

Staffeld,

Gill,

Zimmermann

et al. 2023

Cells

View full text Add to dashboard Cite

Anorexia nervosa (AN) is associated with hyperactivity, amenorrhea, and brain atrophy. The underlying pathophysiology is mostly unknown, and new targets for therapeutic interventions are needed. This study aimed to systematically establish a murine AN model with the parameter extent of starvation, animal age, and length of starvation for functional studies. The activity-based anorexia (ABA) model combines food restriction with running wheel access. Early adolescent and adolescent mice received 40% of their baseline food intake until a 20% or 25% weight reduction was reached (acute starvation). To mimic chronic starvation, body weight loss was maintained for another two weeks. Running activity was examined using wheel sensors, while amenorrhea was investigated by analysis of vaginal smears. Brain sections were used to analyze cerebral cortex volumes. Acute starvation did not lead to either AN-related symptoms, whereas chronic starvation led to hyperactivity and amenorrhea except in the adolescent cohort with 20% weight reduction. Only ABA mice with 25% weight reduction revealed a cortex volume reduction. The optimal parameters to mirror AN-related symptoms included a 25% weight reduction, early adolescent or adolescent mice, and chronic starvation. The ABA model enables functional analysis of the impact of chronic AN on the underlying hormonal, behavioral, and brain pathophysiology.

show abstract

Section: Discussionmentioning

confidence: 99%

Establishment of a Murine Chronic Anorexia Nervosa Model

Staffeld,

Gill,

Zimmermann

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“… 42 While an intranasal olanzapine preparation was developed and studied for the treatment of agitation in schizophrenia and bipolar disorder, it is not FDA approved for clinical use at this time. 46 The safety of IV olanzapine has been established in emergency settings for agitation, although no studies have been dedicated to investigating the pharmacokinetics of this route to our knowledge. 43 , 47 Of note, for both olanzapine combination preparations with fluoxetine (Symbyax) and samidorphan (Lybalvi) there are no clinically significant pharmacokinetic differences when compared to olanzapine monotherapy.…”

Section: Available Formulations and Pharmacokinetic Differencesmentioning

confidence: 99%

Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions

Kolli,

Kelley,

Rosales

et al. 2023

PGPM

View full text Add to dashboard Cite

Olanzapine is one of the most widely used antipsychotics since its initial approval by the US Food and Drug Administration in 1996 and has undergone extensive pharmacokinetic study. Despite being utilized in clinical psychiatry for decades, there remain questions regarding the variety of available formulations, the utility of therapeutic drug monitoring, altered kinetic properties in special populations/medical illnesses, the use of high-dose olanzapine, and drug interactions, among many others. We performed a narrative literature review of olanzapine pharmacokinetics in June 2023 using the US National Library of Medicine’s PubMed.gov resource ( https://www.ncbi.nlm.nih.gov/pubmed ) and Google Scholar. Herein, we review clinically relevant aspects of olanzapine pharmacokinetic data while highlighting knowledge gaps and potential areas of future study.

show abstract

Intranasal administration of olanzapine has beneficial outcome in a rat activity-based anorexia model

Cited by 2 publications

References 40 publications

Establishment of a Murine Chronic Anorexia Nervosa Model

Establishment of a Murine Chronic Anorexia Nervosa Model

Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions

Contact Info

Product

Resources

About